Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

April 29, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors. In terms of ...

Speaking of Sage, news broke recently of an unsolicited buyout offer of $7.22 a share from Biogen that was rejected. To my mind, this speaks to the promise they see in this drug and the team at ...

Sage Steele, a former “SportsCenter” anchor who left the network two years ago after a legal battle over the company’s COVID-19 vaccine policy, said Tuesday there’s “a long list of ...